Cashu
Analysts Split on Apellis Pharmaceuticals' Future Amid Strategic Developments and Market Challenges
24 days ago
Stocks
Health Care
apls
Apellis Pharmaceuticals
NASDAQ: APLS
+23.14 (+135.40%)
40.23
USD
At close at Mar 31, 20:42 UTC
Overview
Loading chart...
Key Stats
Market Cap
2.16B
Dividend Yield
0.00%
P/E Ratio
96.58
EPS
-1.59
Revenue
781.37M
Avg. Volume
2.13M
About
What does APLS do?
Apellis Pharmaceuticals, based in Waltham, Massachusetts, specializes in developing therapies for diseases with high unmet needs, employing 702 staff since its IPO in November 2017. Its approved products include SYFOVRE for geographic atrophy and pegcetacoplan for paroxysmal nocturnal hemoglobinuria.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.